Bedaquiline (TMC207) is the first drug with a new mechanism of action against M. tuberculosis in decades. Microbiologically this diarylquinoline is very potent in vitro and in vivo, but its physicochemical properties are far from ideal. Its development path was paved with ups and downs. FDA granted accelerated approval for Sirturo as part of combination therapy to treat adults with pulmonary Multi-Drug Resistant Tuberculosis

Discovery and development of bedaquiline: A rocky road

247th National Meeting (2014)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.